Circulation

NOVEMBER 11, 2024

Introduction:Mavacamten is a cardiac myosin inhibitor that has been approved for obstructive hypertrophic cardiomyopathy (oHCM). Circulation, Volume 150, Issue Suppl_1 , Page A4123391-A4123391, November 12, 2024.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiomyopathy Heart Failure Pulmonary 40

Circulation

JANUARY 24, 2024

METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.

Heart Disease 81

Heart Disease Peripheral Arterial Disease Strokes Stroke 81

Circulation: Heart Failure

MARCH 8, 2024

Between 2016 and 2018, 3285 MESA participants from 6 field centers underwent comprehensive speckle-tracking echocardiography with passive leg raise maneuver, Kansas City Cardiomyopathy Questionnaire, 6-minute walk test, arterial stiffness assessment, and proteomics (including NT-proBNP [N-terminal pro-B-type natriuretic peptide]).Results:Median

Heart Failure 40

Heart Failure Atherosclerosis Kidney Disease Risk Factors 40

DAIC

FEBRUARY 29, 2024

12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Circulation

NOVEMBER 11, 2024

A 35-year-old gravida 1, para 0 with biventricular heart failure (LVEF 25%), nonischemic cardiomyopathy, history stroke, history of left ventricular thrombus, class III obesity, and chronic kidney disease who had been followed by Cardio-Obstetrics throughout her pregnancy presented at 34 weeks gestation for planned induction of labor.

Heart Failure 40

Heart Failure Cardiogenic Shock ICU Cardiothoracic 40

MIBHS

FEBRUARY 28, 2025

Cardiomyopathies: These diseases affect the heart muscle, impairing its ability to pump blood effectively. Mutations in specific genes often cause hypertrophic cardiomyopathy and dilated cardiomyopathy. Medication and Medical Interventions Sometimes, lifestyle changes alone may not be enough to counteract genetic risks.

Genetic predisposition 52

Genetic predisposition Heart Disease Cholesterol Blood Pressure 52

European Journal of Heart Failure

APRIL 13, 2025

Patients with COPD had a higher risk of the primary endpoint (adjusted rate ratio [RR] 1.44, 95% confidence interval [CI] 1.211.71).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Pulmonary Peripheral Arterial Disease 40

Cardiovascular Diabetology

OCTOBER 23, 2024

Background We aimed to clarify the existence and pathological features of obesity cardiomyopathy (OCM) in Japan using our series of autopsy cases. We compared cases of OCM with those with obesity without cardiac hypertrophy (OB) and normal weight without cardiac hypertrophy (normal control).

Sudden Cardiac Death 52

Sudden Cardiac Death Obesity Cardiomyopathy BMI 52

MIBHS

MARCH 15, 2025

Heavy and repeated binge drinking can lead to alcoholic cardiomyopathy, a condition in which the heart muscle weakens and struggles to pump blood efficiently. Additionally, alcohol contributes to weight gain, as many alcoholic beverages are high in empty calories, leading to an increased risk of obesity and its associated heart complications.

Blood Pressure 52

Blood Pressure Heart Rhythm Blood Clot Heart Disease 52

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. Circulation, Ahead of Print. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 In the STEP-HFpEF trial, once-weekly semaglutide 2.4

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

Circulation

NOVEMBER 17, 2024

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. Circulation, Ahead of Print. n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

We aimed to investigate the safety of intravenous tissue plasminogen activator (IV tPA) and mechanical thrombectomy (MT) for acute ischemic stroke (AIS), and compare the functional outcome in cardiomyopathy patients with and without HF. 37.6%, p < 0.001), obesity (9.2% 24.2%, p < 0.001), diabetes mellitus (39.7%

Heart Failure 40

Heart Failure Cardiomyopathy Inpatient Strokes 40

Cardiometabolic Health Congress

SEPTEMBER 13, 2024

Updated Mayo Clinic HCM Genotype Predictor Score: Iuri Ferreira Felix, MD (USA) presented the updated Mayo Clinic HCM Genotype Predictor Score, a valuable screening tool for identifying hypertrophic cardiomyopathy (HCM) patients with a high likelihood of testing positive for genetic mutations.

Hypertension 59

Hypertension Cardiovascular Disease Bicuspid/Mitral Arrhythmia 59

Cardiometabolic Health Congress

MARCH 8, 2024

She is one of the first fellowship-trained obesity medicine physicians in the world. Anuradha Lala-Trindade, MD: She focuses on the selection and care of patients with mechanical circulatory support devices and heart transplantation, genetic cardiomyopathies, and perioperative management of high-risk cardiac surgical cases.

Cardiac Rehabilitation 59

Cardiac Rehabilitation Academic Diabetes Research 59

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. Investigators randomized 616 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=310) or placebo (n=306).

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Cardiometabolic Health Congress

DECEMBER 5, 2024

SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity. VANISH2 Trial : Catheter ablation as first-line therapy reduced VT episodes more effectively than antiarrhythmic drugs in ischemic cardiomyopathy patients. Access the full study.

CME 52

CME Obesity Innovation Cardiovascular Disease 52

Frontiers in Cardiovascular Medicine

FEBRUARY 20, 2025

BackgroundThe mortality of patients with acute myocardial infarction (MI) raised rapidly in last decade and obesity are becoming the major cause to CAD progression, thus inducing heart failure preserved ejection fraction (HFpEF). Nine hub genes were obtained, including OGN, SELL, FOS, NKG7, LOX, HBB, CXCL9, CP and ALOX5.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Myocardial Infarction Download 52

Cardiometabolic Health Congress

JANUARY 2, 2025

November 2024 Approvals Acoramidis Approval Date: November 22, 2024 Indication: Approved for adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and severe cardiac condition.

Coronary Artery Disease 52

Coronary Artery Disease Stents Stent Innovation 52